Journal article

Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial

Nicole Mittmann, Heather-Jane Au, Dongsheng Tu, Christopher J O'Callaghan, Pierre K Isogai, Christos S Karapetis, John R Zalcberg, William K Evans, Malcolm J Moore, Jehan Siddiqui, Brian Findlay, Bruce Colwell, John Simes, Peter Gibbs, Matthew Links, Niall C Tebbutt, Derek J Jonker

JOURNAL OF THE NATIONAL CANCER INSTITUTE | OXFORD UNIV PRESS INC | Published : 2009

Abstract

BACKGROUND: The National Cancer Institute of Canada Clinical Trials Group CO.17 study showed that patients with advanced colorectal cancer had improved overall survival when cetuximab, an epidermal growth factor receptor-targeting antibody, was given in addition to best supportive care. We conducted a cost-effectiveness analysis using prospectively collected resource utilization and health utility data for patients in the CO.17 study who received cetuximab plus best supportive care (N = 283) or best supportive care alone (N = 274). METHODS: Direct medical resource utilization data were collected, including medications, physician visits, toxicity management, blood products, emergency departme..

View full abstract